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Aberrant activation of Wnt signaling is involved in the development of several epithelial
tumors. Wnt signaling includes two major types of pathways: (i) the canonical or Wnt/β-
catenin pathway; and (ii) the non-canonical pathways, which do not involve β-catenin
stabilization. Among these pathways, theWnt/β-catenin pathway has received most atten-
tion during the past years for its critical role in cancer. A number of publications emphasize
the role of theWnt/β-catenin pathway in thyroid cancer.This pathway plays a crucial role in
development and epithelial renewal, and components such as β-catenin and Axin are often
mutated in thyroid cancer. Although it is accepted that alteredWnt signaling is a late event
in thyroid cell transformation that affects anaplastic thyroid tumors, recent data suggest
that it is also altered in papillary thyroid carcinoma (PTC) with RET/PTC mutations. There-
fore, the purpose of this review is to summarize the main relevant data ofWnt signaling in
thyroid cancer, with special emphasis on theWnt/β-catenin pathway.
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INTRODUCTION
Follicular epithelial thyroid carcinoma is the most common
endocrine malignancy, and its incidence is rapidly rising in the
world. Although thyroid cancer has a very good outcome, there
are still several challenges that classical clinicopathological studies
have not been able to resolve (Riesco-Eizaguirre and Santisteban,
2007). The most recent advances in thyroid cancer research derive
from an increased understanding of the mechanisms that regu-
late thyroid cell differentiation and proliferation and the signal
transduction pathways involved.
Differentiated thyroid cells form follicular structures sur-
rounding a lumen and express a series of thyroid-speciﬁc tran-
scription factors as well as other speciﬁc proteins (reviewed in
De Felice and Di Lauro, 2004; Santisteban and Bernal, 2005).
Thyroid proliferation and differentiation are ﬁnely regulated
by Thyrotropin (thyroid stimulating hormone, TSH) that, after
binding to its receptor (TSHR, a seven-transmembrane recep-
tor coupling to G proteins), activates the cAMP/PKA cascade
(Vassart and Dumont, 1992). Recently our group has shown
that TSH can also act via PI3K/Akt (Zaballos et al., 2008). In
addition, increasing evidence supports a role for other kinases,
such as MAP kinase (MAPK), which are activated in response
to TSH and lie downstream of cAMP (Dumaz and Marais,
2005).
The differentiated thyroid epithelial phenotype is characterized
by structural and functional polarization of the cell surface into
apical and basolateral domains, and the formation of junction
complexes that mediate strong and tight intercellular adhesion.
Cell polarization plays a central role in maintaining follicular
structures and its alteration occurs in parallel with cell transfor-
mation. The presence of tight junctions in thyroid epithelial cells
is thought to be essential for the integrity and maintenance of the
follicular structure. Several molecules are involved in this process;
of these, the occludins, claudins, and zonula occludens (ZO) pro-
teins have been most intensively studied, as they play an important
role in the maintenance of the epithelial cell phenotype. As occurs
with others epithelial markers, their expression is reduced in thy-
roid cancer progression (Tzelepi et al., 2008). On the other hand,
adherens junctions are mainly composed of cadherins. Among
them, E-cadherin and Cadherin 16 are highly expressed in the thy-
roid (Cali et al., 2012). Both are members of the large superfamily
of adhesion molecules and play a critical role in the establishment
of cell polarity and ﬁrm contacts.
Adherens junctions have a similar structural organization as
tight junctions: E-cadherins and Cadherin 16 form contacts with
the catenins (α, β, and γ) and αB-crystallin respectively, and these
latter proteins connectwith the cystokeleton (Cali et al., 2012). The
follicular structure is maintained by a series of proteins through
which TSH and intercellular contact regulate adhesion of follicular
cells to each other and to the extracellular matrix, and inﬂuence
thyroid cell behavior. The extracellular matrix plays a role in the
adhesion, proliferation, differentiation, and migration of thyroid
follicular cells.
It has been reported that downregulation of cadherins takes
place in carcinogenesis and is associated with tumor progression
in a variety of human carcinomas (Strumane et al., 2004; Berx and
van Roy, 2009). Therefore, decreased expression or loss of cad-
herins may lead to the development of epithelial tumors, invasion,
and metastasis. In accordance with this, the loss of E-cadherin and
Cadherin 16 expression in thyroid carcinoma has been correlated
with a loss of differentiation and a poor prognosis (Brabant et al.,
1993; Cali et al., 2012; de Cristofaro et al., 2012).
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THYROID CANCER INITIATION AND PROGRESSION
Thyroid cell proliferation requires the combined effects of TSH,
acting via cAMP, and growth factors such IGF1, signaling pri-
marily through MAPK and phosphatidylinositol-3-kinase (PI3K;
Medina and Santisteban, 2000; Kimura et al., 2001). It is therefore
well accepted that mutations in genes involved in these signal-
ing pathways play prominent roles in the pathogenesis of thyroid
neoplasia.
Currently there are two hypotheses to explain the onset of thy-
roid cancer, the classical multistep model and a theory based on
cancer stem cells (CSCs).
The classical view considers thyroid carcinoma as a complica-
tion of a pre-existing follicular adenoma (FA) accumulating muta-
tions that drive progression through a dedifferentiation process.
Accordingly, a step model of thyroid carcinogenesis involving dif-
ferent deﬁned types of thyroid tumor is well accepted (Figure 1).
Thus, autonomously hyperfunctioning thyroid adenomas and FAs
are benign tumors that rarely progress to malignancy. Papil-
lary thyroid carcinoma (PTC) and follicular thyroid carcinoma
(FTC) show follicular cell differentiation, andpoorly differentiated
carcinomas (PDC) have morphological and biological character-
istics intermediate between well-differentiated and undifferenti-
ated (anaplastic) thyroid carcinomas (ATC; reviewed in Riesco-
Eizaguirre and Santisteban, 2007, and inNikiforov andNikiforova,
2011).
The genetic events involved in tumor initiation have been iden-
tiﬁed in well-differentiated thyroid cancer. In PTC there are many
data supporting a central role of mutations leading to constitutive
activation of the MAPK pathway. Thus, the V600E mutation of
BRAF, RET/PTC rearrangements, and RAS mutations have been
clearly implicated in the pathogenesis of this disease. These three
pathways are mutually exclusive and it is accepted that they are
the cause of a signiﬁcant proportion of PTCs. Similarly, there is
increasing evidence that shows that cancer genes acting through
the PI3K pathway (PI3KCA and PTEN ) are involved in the patho-
genesis of FTC. However, in this case more studies are needed to
elucidate a possible causal effect of these genetic events. Further-
more, a PAX8/PPARγ rearrangement (Kroll et al., 2000) has been
identiﬁed in a signiﬁcant proportion of these tumors, although
the mechanism of transformation induced by PAX8/PPARγ is still
unclear.
Deregulation of the p53 pathway seems to be an important sec-
ond step leading to the progression of PDC/ATC (Fagin et al., 1993;
Figures 1 and 2). In addition, activatingmutations in the β-catenin
gene (CTNNB1) have been described inATC that occur late in thy-
roid tumor progression. Therefore, until the recent demonstration
that RET/PTC stimulates the β-catenin pathway in the thyroid
(Cassinelli et al., 2009; Castellone et al., 2009; Tartari et al., 2011),
it was believed that β-catenin was not involved in thyroid tumor
initiation. Compared with the well-documented RAS/RAF/MAPK
pathway, the β-catenin signal in thyroid cancer is less well under-
stood, and therefore in this review we will focus on updating the
existing data and comment on future directions of research.
Recently, a new theory on the cancer initiation process was for-
mulated, based on the existence of CSCs (Thomas et al., 2008;
Lin, 2011). These CSCs are a small subpopulation (between 1 and
3.5%) of the cells with stem cell-like properties such as colony
formation, self-renewal, and in vitro resistance to chemotherapy-
induced apoptosis (Dick, 2008, 2009). In the case of the thyroid
gland, the CSCs would derive from thyroid embryonic stem cells,
intermediates in the differentiation pathway of thyroblasts or pro-
thyrocytes, and accumulate mutations that lead to carcinogenesis.
TheCSChypothesis assumes the presence of a hierarchy of embry-
onic cells in the thyroid gland that can give rise to different forms
of thyroid cancer (reviewed in Lu et al., 2011).
The existence of CSCs in the thyroid is still a matter of contro-
versy,but several lines of evidence support themodel.Among them
is the observation that it is uncommon that a benign adenoma
FIGURE 1 | Step model of thyroid carcinogenesis.This model is
based on histological and clinical features as well as on the degree of
tumor differentiation. The well-differentiated thyroid follicular cell may
give rise to both benign and malignant tumors. Autonomously
hyperfunctioning thyroid adenomas are associated with activating
mutations in theTSHR or Gαs genes (O’Sullivan et al., 1991; Parma
et al., 1993). After gaining mutations in different oncogenes and tumor
suppressor genes, the differentiated thyroid follicle can also give rise to
well-differentiated papillary or follicular carcinomas, poorly
differentiated carcinoma, and anaplastic carcinoma. The ﬁgure
represents a schematic model showing the molecular events involved.
Modiﬁed from Nikiforov and Nikiforova (2011).
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FIGURE 2 | Genetic events involved in thyroid tumor initiation and
progression.Thyroid cell proliferation depends on the combined activation
of cAMP/PKA, MAPK, and PI3K pathways, induced byTSH and other growth
factors. Mutations of effectors along these signaling pathways play
prominent roles in the pathogenesis of thyroid neoplasia. The ﬁgure
represents a thyroid epithelial cell with the basal and apical membrane, and
shows the tight and adherens junctions (TJ and AJ) between cells in order to
form follicular structures. Activating mutations inTSHR or Gαs lead to
constitutive activation of the cAMP/PKA pathway and give rise to
hyperfunctional adenomas. There is evidence that constitutive activation of
the MAPK pathway is required for PTC initiation. Activation of the PI3K/Akt
pathway is required for FTC initiation. Finally, deregulation of the p53
pathway and theWnt/β-catenin pathway is observed in ATC and has more to
do with tumor progression.
evolves toward carcinoma; at present, it seems that most thyroid
carcinomas are malignant from the onset; the original RET/PTC
mutations seen in FTC and PTC are hardly seen in ATC. In addi-
tion, data from Chernobyl irradiation studies, in which the highest
incidence of papillary thyroid cancer was among children rather
than adults, strongly support the CSC theory. The establishment
of ES cell cultures able to differentiate into thyrocytes may help
clarifying these views (Arufe et al., 2006).
Wnt SIGNALING
Wnt proteins are a family of highly conserved secreted cysteine-
rich glycoproteins, encoded by 19 genes in humans and 18 genes
in mice. These proteins play important roles in embryonic devel-
opment by controlling cell proliferation, cell fate speciﬁcation,
tissue patterning, and cell polarity. In adults, they contribute to
tissue homeostasis by controlling proliferation, stem cell activa-
tion, and self-renewal. Signaling by Wnt proteins activates three
different pathways: one canonical or β-catenin-dependent path-
way and two non-canonical or β-catenin-independent pathways:
Wnt/Ca2+ and planar cell polarity (PCP; Figure 3). The relevance
of these pathways is also reﬂected by the fact that mutations in
some elements of the Wnt pathways are often linked to human
diseases like leukemia and other cancers, and type-II diabetes
(Kikuchi and Yamamoto, 2008; MacDonald et al., 2009).
CANONICAL Wnt/β-CATENIN PATHWAY
The most extensively studied Wnt pathway is the Wnt/β-catenin
pathway, due to its important role in cancer initiation and pro-
gression (Reya and Clevers, 2005; see Figure 3, left). In the absence
of Wnt, β-catenin, the central component of the pathway, is local-
ized in adherens junctions bound to E-cadherin. The unbound
cytoplasmic protein is constantly degraded by a protein complex
called destruction complex, which is composed of the scaffold
proteins Axin and adenomatous polyposis coli (APC), and the
kinases casein kinase 1 (CK1) and glycogen synthase kinase 3
beta (GSK3β; Rubinfeld et al., 1996). CK1 and GSK3β sequen-
tially phosphorylate β-catenin, resulting in β-catenin being recog-
nized and ubiquitinated by the β-Trcp ubiquitin ligase, followed
by proteasomal degradation. With low levels of free cytoplas-
mic β-catenin, the transcription factors T-cell factor/lymphoid
enhancer factors (TCF/LEF) function as transcriptional repressors
by recruiting corepresors of the TLE/Groucho family.
The Wnt pathway is activated when a protein of the fam-
ily, such as Wnt1, Wnt3, Wnt3a, Wnt7A, or Wnt10B, binds
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FIGURE 3 |Wnt signaling pathways. Left : Canonical orWnt/β-catenin
dependent pathway. In cells not exposed toWnt factors, cytoplasmic
β-catenin is degraded, andTLE/Groucho proteins repress its target genes.
If Wnt signaling is activated by binding ofWnt factors such asWnt1,Wnt3,
Wnt3A,Wnt7A, orWnt10B to the Fzd receptor and LRP5/6 coreceptors,
β-catenin degradation is reduced and the protein accumulates in the
cytoplasm. As a consequence, β-catenin enters the nucleus, binds to
TCF/LEF transcription factors and activates transcription. In this way,
different processes such as proliferation are modulated. Right :
Non-canonical or β-catenin-independent pathways. Binding of the
non-canonicalWnt factorsWnt4,Wnt11, orWnt5A to different Fzd receptors
and the Ror2 coreceptor transduce signaling by two different pathways. The
Ca2+ pathway promotes the activation of protein kinase C (PKC) via G-PLCγ
and modulates cell adhesion and motility by activating calcium–calmodulin
kinase (CamKII), and the phosphatase calcineurin (CaN). The planar cell
polarity (PCP) pathway modulates cytoskeleton rearrangements through the
activation of the small GTPases RhoA and Rac and their downstream
effectors Rock and JNK.
to a frizzled receptor (Fzd) and the LDL-Receptor-related pro-
tein coreceptor (LRP5/6). Formation of a Wnt–Fzd–LRP com-
plex induces the binding of the cytoplasmic protein Disheveled
(Dvl) to Fzd and the LRP phosphorylation-dependent recruit-
ment of Axin to the membrane. Recruitment of Axin, which is
the limiting component of the destruction complex, promotes
the release of β-catenin, and its accumulation in cytoplasm and
nuclei. In the nuclei, β-catenin displaces TLE/Groucho core-
pressors and recruits coactivators, activating expression of Wnt
target genes. The meanings of the acronyms used for the dif-
ferent members of the Wnt pathway are given in Table 1; see
http://www.stanford.edu/group/nusselab/cgi-bin/wnt/ for more
details.
The most important genes regulated are those related to
proliferation, such as Cyclin D1 and c-Myc (He et al., 1998;
Tetsu and McCormick, 1999), which are over-expressed in most
β-catenin-dependent tumors.
NON-CANONICAL Wnt PATHWAYS
There are two main β-catenin-independent pathways (see
Figure 3, right). The activation of these pathways is mediated
by Wnt factors such Wnt4, Wnt11, and Wnt5A in a tissue and
context speciﬁc way. The ﬁrst pathway is the PCP pathway. This
pathway can be triggered through several of the Fzd receptors
and it activates the small GTP-binding proteins RhoA and Rac
and their downstream effectors Rho-kinase and JNK. This non-
canonical pathway is involved in tissue polarity, cell migration,
and cytoskeleton organization. It has been described inDrosophila,
and although its relevance in mammals has not been fully demon-
strated, there is important evidence pointing to its existence in
these vertebrates (Wada andOkamoto, 2009). The second pathway
is the Ca2+ pathway,which can be activated by the interaction with
two Fzd receptors (Fzd 2 and 7) or with Ror2 (receptor tyrosine
kinase-like orphan receptor 2). The activationof this pathway leads
to an activation of PKC and to increased intracellular Ca2+ levels,
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Table 1 | Members of theWnt pathway grouped according to function.
β-Catenin destruction complex APC1/2 (adenomatous polyposis coli)
Axin 1/2
GSK3β (glycogen synthase kinase 3 beta)
CK1 (casein kinase 1)
Receptor/co-receptors Fzd 1–10 (frizzled)
LRP5/6 (LDL receptor related protein) co-receptor
Ror2 (receptor tyrosine kinase-like orphan receptor 2)
Dvl 1–3 (dishevelled: cytoplasmic protein downstream of Fzd receptors)
Wnt ligands β-catenin-dependent pathway activators Wnt1, 2, 2B, 3, 3A, 6, 5B, 7A, 7B, 8A, 8B, 9A, 9B, 10A, 10B, 16
β-catenin-independent pathways activators Wnt4, 5A, and 11
Transcription factors TCF1, 3, and 4; Lef1 (T-cell factors; lymphoid enhancer factor)
Transcriptional co-activators β-catenin
Transcriptional co-repressors TLE (transducin-like enhancer of split)/Groucho 1–4
Wnt inhibitors DKK 1–4 (dickkopf)
SFRP 1–5 (secreted frizzled-related proteins)
Soggy andWIF
which activates CaMKII and calcineurin (CaN) and regulates cell
migration and proliferation (Nishita et al., 2010).
Wnt INHIBITORS
Activation of the Wnt pathway is highly regulated, and there are
two families of antagonists: DKK and secreted frizzled-related
proteins (SFRP). The Dickkopf (DKK) family is a group of four
soluble proteins that bind to LRP and thus prevent the formation
of the Wnt–Fzd complex. The SFRP are soluble glycoproteins that
inhibit the Wnt pathway by sequestering Wnt proteins, thus pre-
venting their interaction with Fzd receptors. There are other Wnt
inhibitors like WIF or Soggy1 (Filipovich et al., 2011; Figure 3).
The physiological role of these proteins is to inhibit the Wnt
pathway in a time and tissue-speciﬁc manner both during devel-
opment and in adult tissues. The silencing of DKK and SFRP
genes has been described in several tumor types, contributing to
the activation of the canonical pathway (Aguilera et al., 2006).
Wnt AND THYROID CANCER
Normal thyroid cells express several Fzd, Dvl, and Wnt proteins
and have a functional destruction complex (Helmbrecht et al.,
2001). In addition,TSH-dependent over-expression of Wnt1 (Kim
et al., 2007) and inhibition of GSK3β by adenoviral-interference
(Chen et al., 2010) lead to an increase of rat and human thyroid
cell proliferation. These data suggest the existence of a functional
Wnt pathway, relevant for the proliferation of thyroid cells.
Given the hypothetical role of this pathway in proliferation, it is
not surprising that over-activation of the Wnt/β-catenin pathway
promotes tumor growth in the thyroid, as in otherWnt-dependent
tissues like skin or colon.
Classically, activation of the Wnt pathway in thyroid can-
cer has been related with ATCs, as a second mutational event
involved in the progression from a well-differentiated to a poorly
or undifferentiated (anaplastic) and more aggressive thyroid car-
cinoma. However, as commented above, recent data correlate this
pathway also with early stages of thyroid carcinogenesis.
Wnt IN POORLY DIFFERENTIATED AND ANAPLASTIC THYROID
CARCINOMA
Mutations of several components of the Wnt pathway have been
described inATC (Table 2). Themost frequentmutations are those
in the scaffold proteins APC and Axin, as well as in β-catenin
(Polakis, 2007). In tumors such as colon tumors mutations most
frequently affect the APC gene, but in the thyroid the mutations
appear mainly in β-catenin and Axin.
In ATC, three different studies found nuclear localization
of β-catenin in 40–60% of the samples analyzed, highlighting
the role of the Wnt pathway in this type of tumor (Garcia-
Rostan et al., 1999, 2001; Kurihara et al., 2004). In these stud-
ies, performed in three different human populations, mutations
in the β-catenin and Axin1 genes were described. In two of
them, all β-catenin mutations found were in the conserved Ser
and Thr residues phosphorylated by CK1 and GSK3β, which
results in a constitutive stabilization of the protein and succes-
sive accumulation in both cytoplasm and nucleus. The pres-
ence of nuclear β-catenin correlated with a higher proliferation
and a loss of tumor differentiation, and therefore with a poor
prognosis (Garcia-Rostan et al., 1999, 2001). Despite the role
of β-catenin in proliferation, these latter two studies together
with another one (Cerrato et al., 1998) also described a per-
centage of anaplastic tumors in which the β-catenin expression
is absent.
These data can be interpreted to mean that there are distinct
subtypes of tumors in ATC with different, mutually exclusive
mutations. Thus, one subtype would carry the Wnt/β-catenin
pathway mutation, while the other would carry the p53 muta-
tion (Fagin et al., 1993) or an activated PI3K/Akt pathway, e.g.,
through a mutation in PI3KCA (Garcia-Rostan et al., 2005); these
three are the most frequent mutations found in ATC. It would be
of great interest to establish whether mutations in oncogenes or
tumor suppressor genes are mutually exclusive in order to better
classify anaplastic thyroid tumors.
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By contrast, the study by Kurihara et al. (2004) described a
low percentage of β-catenin mutations, while more than 50%
of the tumors carried mutations in the functional domain of
Axin1. The different mutations found in the Axin1 gene affect
the domains for interaction with APC, β-catenin and Dvl, and the
G-protein regulatory domain, and thus affect the role of Axin as
a negative regulator of β-catenin. The difference in data regarding
β-catenin and Axin mutations may be due to the different genetic
backgrounds of the populations analyzed.
Wnt IN WELL-DIFFERENTIATED THYROID CARCINOMA
It is well accepted that there is a correlation between the subcellular
localization of β-catenin and cancer progression (Garcia-Rostan
et al., 2001). In hyperfunctioning adenomas and FTC, β-catenin is
localized in the plasma membrane, as it is in the normal thyroid
gland. In PTC, there is an accumulation of β-catenin in the cyto-
plasm, and in poorly and undifferentiated carcinoma β-catenin
is translocated to the nuclei due to mutations in the β-catenin
gene as well as in other genes of the Wnt pathway (Table 3).
We already discussed the role of β-catenin in ATC, but the role
and the molecular mechanisms that lead to the cytoplasmic sta-
bilization of β-catenin have not been established. Some groups
have correlated cytoplasmic β-catenin in PTC with higher lev-
els of cyclin D1 (Ishigaki et al., 2002; Meirmanov et al., 2003;
Rezk et al., 2004; Zhang et al., 2011) and increased prolifera-
tion. Nevertheless, at present there are no in vitro results that
corroborate this hypothesis and no relationship between cytoplas-
mic β-catenin and transcriptional activity has been found. More
studies are needed to demonstrate a direct link between cytoplas-
mic β-catenin and cyclin D1 expression in order to correlate both
events with proliferation.
E-cadherin is a transmembrane protein that mediates cell–cell
adhesion in a Ca2+-dependent manner. It interacts through its
cytoplasmic domain with β-catenin and the actin cytoskeleton,
controlling cell migration and cell polarity (Hulsken et al., 1994).
In normal thyroid cells, E-cadherin is expressed in the basolateral
Table 2 | Events linked with aberrant activation ofWnt signaling in thyroid cancer.
Gene Mutation or activity/expression Tumor No. of cases Reference
CTNNB1* GOF ATC 19/31 Garcia-Rostan et al. (1999)
ATC (PD) 7/28 Garcia-Rostan et al. (2001)
ATC (UD) 19/29 Garcia-Rostan et al. (2001)
Axin 1 LOF ATC 18/22 Kurihara et al. (2004)
APC LOF CMV–PTC 4/4 Cetta et al. (1998)
15/15 Cetta et al. (2000)
Wnt5A Elevated FTC/PTC 8/8–10/11 Kremenevskaja et al. (2005)
Wnt5A Reduced ATC 5/5 Kremenevskaja et al. (2005)
*β-catenin gene; GOF, gain of function; LOF, loss of function; FTC, follicular thyroid carcinoma; PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid carcinoma;
PD, poorly differentiated; UD, un-differentiated; CMV–PTC, cribriform–morular variant of PTC.
Table 3 | Localization of β-catenin in thyroid carcinoma.
Tumor type Cytoplasmic expression Nuclear expression No. of cases Reference
FA 3 (9%) 34 Ishigaki et al. (2002)
3 (37.5%) 8 Meirmanov et al. (2003)
FTC 5 (25%) 20 Ishigaki et al. (2002)
8 (80%) 10 Rezk et al. (2004)
8 (60%) 12 Garcia-Rostan et al. (2001)
PTC 46 (100%) 46 Garcia-Rostan et al. (2001)
46 (87%) 53 Rezk et al. (2004)
52 (67%) 78 Ishigaki et al. (2002)
23 (100%) 23 Meirmanov et al. (2003)
FVPTC 33 (71%) 46 Garcia-Rostan et al. (2001)
ATC (PD) 6 (24.1%) 28 Garcia-Rostan et al. (2001)
ATC (UD) 14 (48.3) 29 Garcia-Rostan et al. (2001)
ATC 15 (41%) 36 Garcia-Rostan et al. (1999)
10 (49%) 14 (63.6%) 22 Kurihara et al. (2004)
FA, follicular adenoma; FVPTC, follicular variant of PTC; the other acronyms of tumor type as deﬁned inTable 2.
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membrane and its downregulation, by promoter methylation or
by activation of oncogenes such as BRAF, has been implicated in
the induction of the epithelial mesenchymal transition (EMT) in
follicular, papillary, and anaplastic thyroid tumor cells (Brabant
et al., 1993; Graff et al., 1998; Riesco-Eizaguirre et al., 2009). As
E-cadherin keeps β-catenin bound to the cell membrane, the pres-
ence of cytoplasmic β-catenin could be merely a consequence of
the loss of E-cadherin expression, although this correlation has
not yet been demonstrated.
Supporting the role of β-catenin in earlier stages of tumor
progression, recent publications describe the involvement of β-
catenin in RET/PTC-induced proliferation (Cassinelli et al., 2009;
Castellone et al., 2009; Tartari et al., 2011). These studies show
a RET/PTC-dependent stabilization of β-catenin by phospho-
rylation of a residue outside the GSK3β Ser/Thr domain. This
stabilization, together with an Akt–MAPK-dependent inhibition
of GSK3β, leads to an increase of β-catenin in the nuclei where
it is able to interact with the transcription factors TCF/LEF and
CREB binding to the cyclin D1 promoter. In consequence, DNA
synthesis and cell proliferation are induced. This is another way of
Wnt/β-catenin pathway regulation, by post-translational modiﬁ-
cations, that points to a participation of this pathway in the ﬁrst
steps of thyroid cell transformation. Unfortunately, the authors
did not correlate their results with the localization of β-catenin in
RET/PTC-carrying thyroid tumors.
Data obtained from the TRβPV/PV mouse model of FTC
that harbors a dominant negative mutation (PV) of the thyroid
hormone-beta receptor (TRβ), also support the notion that β-
catenin could contribute to thyroid carcinogenesis (Guigon et al.,
2008; Lu et al., 2011). Thus, in the FTC tumors of these mice
thyroid hormone and its receptors seem to modulate the Wnt/β-
catenin pathways in two ways. First, the TRβ acts as negative regu-
lator of β-catenin in a T3-dependent manner (Guigon et al., 2008).
In the absence of ligand, TRβ binds to β-catenin and stabilizes it
in the cytoplasm and the nuclei allowing β-catenin to operate as
a transcriptional activator promoting cell proliferation. Binding
of T3 to TRβ weakens the physical interaction between β-catenin
and TRβ and allows the uncomplexed β-catenin to be targeted
for proteasomal degradation. In the thyroid tumors developed in
the transgenic TRβPV/PV mice, β-catenin is constitutively stabi-
lized through its binding to the mutant TRβ, because the mutated
TRβ cannot bind T3. In this way, β-catenin activates the expres-
sion of its target genes cyclin D1, myc, and MT1-MMP (matrix
metalloproteinase), and promotes tumor growth and progression.
The second mechanism involves a non-genomic action: T3 (ele-
vated in theTRβPV/PV mice) is able to increase the PTEN/PI3K/Akt
pathway through the αvβ3 receptor, leading to the phosphoryla-
tion of β-catenin, which increases its stability and transcriptional
activity and promotes cell proliferation (Lu et al., 2011). Over-
all, these results show a new mechanism of activation of the
Wnt/β-catenin pathway, which through the stabilization of β-
catenin could be promoting cancer progression in the thyroid
gland.
All the above evidence points to a role of β-catenin in well-
differentiated thyroid carcinomas, but more in vitro and in vivo
evidence is needed and the molecular mechanism remains to be
resolved.
NON-CANONICAL Wnt PATHWAYS IN THYROID CARCINOMAS
Wnt5A is an activator of the non-canonical Wnt pathways. Due to
its roles in planar polarity and cell migration and invasiveness,
Wnt5A has been implicated in several human cancers, but, as
occurs in normal tissues, the roles of Wnt5A in cancer are tis-
sue and receptor speciﬁc. In osteosarcoma as well as in prostate
and renal cell carcinomas, Wnt5A acting through the Ror2 recep-
tor is involved in matrix metalloprotease expression, enhancing
cell migration and invasiveness of these cells, and consequently it
is a poor prognosis factor for these types of tumors. By contrast,
in colon and thyroid tumors Wnt5A acts as a tumor suppressor,
highlighting the variety of roles of this Wnt member (McDonald
and Silver, 2009).
While Wnt5A is expressed in FA, PTC, and FTC, no expression
has been detected inATCor in the normal thyroid (Kremenevskaja
et al., 2005). In well-differentiated cancer cells, Wnt5A acts as a
tumor suppressor by inhibiting both Wnt/β-catenin-dependent
proliferation in a Ca2+/CaMKII dependent manner, and migra-
tion and invasiveness. In this way, it promotes a mesenchymal
epithelial transition (MET) by the induction of cadherin expres-
sion and the re-localization of β-catenin from the nuclei to
the membrane. Wnt5A expression is lost in anaplastic carci-
noma, leading to a more aggressive tumor in which proliferation,
migration, and invasiveness are enhanced.
Wnt IN FAMILIAL SYNDROMES
Sporadic mutation of the APC gene is less frequent in thyroid
tumors, but there is a high frequency of PTC in several syndromes
carrying APC mutations, such as familial adenomatous polyposis
(FAP),Gardner’s syndrome, and Turcot’s syndrome (Soravia et al.,
1999). FAP arises as a consequence of germinal mutations in one
allele of the APC gene. Patients develop mainly colonic polyps and
non-colonic malignancies, the most frequent being PTC. These
PTCs have characteristic histological structures and are called the
Cribriform–Morular Variant of PTC (CMV of PTC), because of
their morula-like structure. Such structures are frequent in other
tumors and correlate with nuclear β-catenin and activation of the
Wnt/β-catenin pathway. Contrary to colorectal neoplasms that
exhibit a loss of heterozygosity in the APC gene, the CMV of
PTC maintains heterozygosity and seems to need other gene alter-
ations to originate a tumor. RET–PTC rearrangements have been
described as a frequent event in CMV PTC-FAP tumors, further
suggesting that APC mutation alone is not sufﬁcient as a tumor
initiator (Cetta et al., 1998, 2000).
Mutations in the phosphorylation sites of β-catenin are also
found in the CMV of PTC,where nuclear localization of β-catenin
correlates with poorly or undifferentiated tumors. In one study it
was suggested that a mutation in exon 3 of the β-catenin gene,
CTNNB1, could be an early molecular event in the CMV of PTC,
although mutations in other genes frequently altered in PTC, such
as RET, RAS, or BRAF were not studied (Xu et al., 2003).
CANCER STEM CELLS AND THE Wnt PATHWAY
Wnt proteins contribute to the homeostasis of several tissues of
epithelial origin, like intestine and skin. This is because activation
of the Wnt pathway is absolutely required for driving the stem
cell/progenitor compartment. This pathway is altered in thyroid
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malignancies, together with other stem cell-regulating pathways
such as Hedgehog and Notch signaling, which supports the CSC
model (reviewed in Derwahl, 2011).
In fact, it is well accepted that the Wnt/β-catenin pathway is
also necessary for the maintenance of CSCs. Thus, in colon the
inappropriate activation of this pathway by APC or β-catenin
gene mutations promotes the growth of tumor cells exhibit-
ing a stem cell-like expression proﬁle (Vermeulen et al., 2010).
In breast cancer, the Wnt pathway is upregulated in CSCs by
Wnt ligands secreted by the tumor microenviroment (Malanchi
et al., 2011). Concerning thyroid CSCs there are still few data,
but increasing evidence supports the existence of CSCs and the
role of the Wnt pathway in this gland. Recent data demonstrate
that CSCs from different types of thyroid carcinomas (PTC, FTC,
and ATC), have different properties: CSCs isolated from ATC are
the most aggressive and tumorogenic, followed by CSCs from
PTC and FTC (Todaro et al., 2010). These data demonstrate that
the malignancy of the CSCs correlates with the characteristics
of the tumor and could reconcile the multistep process of thy-
roid carcinogenesis with the CSC hypothesis (Derwahl, 2011).
Interestingly, the data reported by Todaro et al. showed con-
stitutive activation of cMet, Akt, and β-catenin, together with
downregulation of E-cadherin, in CSCs derived from the most
undifferentiated thyroid tumors. This correlated with a higher
migration capacity and metastatic rate. Although the above results
are very promising, further studies are needed to evaluate the
activation of the Wnt pathway and its role in CSC stemness or
maintenance.
THE Wnt PATHWAY AS A TARGET FOR THYROID CANCER TREATMENT
Thyroid cancer has, in general terms, a very good outcome as
radioiodine treatment is a very effective therapy. However, there
are still some critical challenges that the classical clinicopatho-
logical approach has not been able to solve, and in some poorly
differentiated radioiodine-resistant tumors and in ATC treatment
options are limited.
In the past years, new drugs such as tyrosine kinase inhibitors
or MAPK inhibitors proved to be quite efﬁcient. The ﬁndings
regarding the involvement of the Wnt pathway in thyroid can-
cer, its crosstalk with thyrosine kinase receptors such as RET and
the involvement of β-catenin and Axin in ATC suggest that this
pathway may be a potential therapeutic target. Current therapies
with tyrosine kinase inhibitors such as Imatinid or Vandetanib
seem to work in part by inhibiting the Wnt/β-catenin pathway.
Treatment with Imatinid of anaplastic human cells, positive for
the tyrosine kinase c-abl, induced a decrease in cell proliferation
and invasiveness by reducing nuclear β-catenin and increasing β-
catenin/E-cadherin binding to the plasma membrane. Imatinid
attenuated TCF activity, which in turn reduced expression of its
target gene cyclin D1 leading to cell growth arrest (Rao et al.,
2006). Treatment with Vandetanib of papillary TPC1 cells car-
rying a RET/PTC rearrangement also stabilized β-catenin in the
plasma membrane, decreasing the expression of β-catenin target
genes such as c-myc and cyclin D1, and decreasing cell growth
and migration (Tartari et al., 2011). These results underscore
the importance of Wnt pathway activation in thyroid cancer
progression.
Interestingly, non-steroidal anti-inﬂammatory drugs such as
Sundilac, which target theWnt/β-catenin pathway, have been used
in colon cancer treatment (Rice et al., 2003). Sundilac also reduces
β-catenin expression, which is accompanied by a decrease in cell
growth in human PTC cell lines overexpressing BRAFV600E but not
RET/PTC3 (Cho et al., 2010).
Finally, a conditionally replicative adenovirus harbouring the
E1A and E1B expression under the control of TCF response ele-
ments has been reported. These constructs replicate speciﬁcally
in cells with an active Wnt/β-catenin pathway. This therapeu-
tic approach has been used in xenograft tumors in nude mice
developed from several thyroid cancer cell lines with good results
regarding tumor size reduction, and should be further developed
in the future (Abbosh et al., 2007).
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
It has become evident that the Wnt pathways are involved in
thyroid cancer progression.
Wnt/β-catenin-independent pathways appear to act as tumor
suppressors, because downregulation of Wnt5A, an activator of
the non-canonical pathways, is needed to enhance the migratory
and invasive capacity of thyroid tumor cells. The Wnt/β-catenin-
dependent pathway, on the other hand, seems to be involved in the
proliferation of normal thyroid cells, which is a highly controlled
process.
In the earliest stages of progressionof tumors such as FAorwell-
differentiated FTC and PTC,β-catenin remains mainly attached to
the cell membrane, but begins to appear in the cytoplasm. In these
early stages, tumors carrying RET/PTC rearrangements prolifer-
ate in a β-catenin-dependent way. Although in cell culture this
enhanced proliferation correlates with nuclear accumulation of
β-catenin and high expression of the cyclin D1 and c-Myc genes,
in tumor samples no such correlations were found and β-catenin
was visible only in the cytoplasm. Further studies are needed to
understand the correlation between cytoplasmic β-catenin, the
expression of its cell cycle target genes, and the role of β-catenin
in these tumors.
In poorly and undifferentiated carcinomas, β-catenin is found
in the nuclei, and mutations in this gene or in other genes of the
pathway such as Axin1 induce the constitutive activation of the
canonicalWnt pathway,which triggers an increase in proliferation.
In conclusion, β-catenin has a direct role in the proliferation of
poorly and undifferentiated thyroid tumor cells, but more studies
are needed to establish the role of β-catenin in earlier stages of
thyroid tumor progression.
The use of animal models like APCMin or ΔNβ-catenin mice,
which have a constitutively activated Wnt/β-catenin pathway,
could be of great interest for better understanding the mechanism
by which the Wnt pathway promotes tumor growth in thyroid
cancer.
The Wnt/β-catenin pathway is involved in the transformation
of a large number of tumors, and for this reason in the past few
years several groups have been looking for speciﬁc inhibitors of
this pathway. These inhibitors act through several mechanisms:
increasing the stability of the destruction complex (Huang et al.,
2009) in order to decrease cytoplasmic and nuclear β-catenin
levels, or disrupting the interaction between β-catenin and the
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transcription factors TCF/LEF (Lepourcelet et al., 2004) abolish-
ing the transcription of cell cycle genes. The development of these
inhibitors could contribute to the treatment of thyroid carcino-
mas, especially some anaplastic carcinomas, which show a clear
activation of the Wnt/β-catenin pathway and have a poor prog-
nosis due to their aggressiveness and the loss of differentiation
markers.
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